Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Share this content:
Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies
Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies

Women with myeloproliferative neoplasms appear to have successful pregnancies with better outcomes than would be anticipated from previously published reports, according to a study published in the British Journal of Haematology.1

Evidence suggests that women with myeloproliferative neoplasms such as polycythemia vera and essential thrombocythemia have a higher risk of maternal and fetal complications, which ultimately poses challenges during pregnancy.

To examine maternal and fetal outcomes of women with myeloproliferative neoplasms, researchers analyzed data from 58 pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis who participated in the United Kingdom Obstetric Surveillance System between 2010 and 2012.

During that period, there were 58 live births. Results showed that the incidence of miscarriage was 1.7% (95% CI, 0.04-9.24) and the perinatal mortality rate was 1.7% (95% CI, 0.44-92.36), including both live and stillbirths.

Researchers also found that the incidence of pre-eclampsia, postpartum hemorrhage, and postpartum hematoma were 9%, 9%, and 3.5%, respectively. No maternal deaths or thrombotic events were reported.

A total of 45% of mothers required induced delivery, with all undergoing Caesarean section. Most women delivered at term, with 22% of neonates being below the tenth percentile for growth and 13% requiring admission to the neonatology unit.

Of note, there were no neonatal deaths.


1. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14289. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs